4.4 Review

The use of polygenic risk scores to identify phenotypes associated with genetic risk of schizophrenia: Systematic review

Journal

SCHIZOPHRENIA RESEARCH
Volume 197, Issue -, Pages 2-8

Publisher

ELSEVIER
DOI: 10.1016/j.schres.2017.10.037

Keywords

Polygenic risk score; Schizophrenia; Genetic; Phenotypes

Categories

Funding

  1. Mental Health Research UK
  2. Welsh Clinical Academic Track
  3. NIHR Bristol Biomedical Research Centre
  4. Economic and Social Research Council [ES/S008349/1] Funding Source: researchfish
  5. Medical Research Council [MR/L010305/1, MR/L023784/2, UKDRI-3003, G1001799, MR/N01104X/1, MR/N01104X/2, MR/P005748/1] Funding Source: researchfish
  6. Wellcome Trust [213422/Z/18/Z] Funding Source: researchfish
  7. ESRC [ES/S008349/1] Funding Source: UKRI
  8. MRC [MR/P005748/1, MR/N01104X/1, UKDRI-3003, MR/N01104X/2, G1001799, MR/L023784/2] Funding Source: UKRI

Ask authors/readers for more resources

Studying the phenotypic manifestations of increased genetic liability for schizophrenia can increase our understanding of this disorder. Specifically, information from alleles identified in genome-wide association studies can be collapsed into a polygenic risk score (PRS) to explore howgenetic risk ismanifestwithin different samples. In this systematic review, we provide a comprehensive assessment of studies examining associations between schizophrenia PRS (SZ-PRS) and several phenotypic measures. We searched EMBASE, Medline and PsycINFO (from August 2009-14th March 2016) plus references of included studies, following PRISMA guidelines. Study inclusion was based on predetermined criteria and data were extracted independently and in duplicate. Overall, SZ-PRS was associated with increased risk for psychiatric disorders such as depression and bipolar disorder, lower performance IQ and negative symptoms. SZ-PRS explained up to 6% of genetic variation in psychiatric phenotypes, compared to <0.7% in measures of cognition. Future gains fromusing the PRS approach may be greater if used for examining phenotypes that are more closely related to biological substrates, for scores based on genepathways, and where PRSs are used to stratify individuals for study of treatment response. As it was difficult to interpret findings across studies due to insufficient information provided by many studies, we propose a framework to guide robust reporting of PRS associations in the future. Crown Copyright (c) 2017 Published by Elsevier B. V. All rights reserved.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.4
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available